GlassScriptPhysician profile
Zia M Sheikh
NPI 1144222340
$91,503.80
in general payments reported to CMS, 2019-2025
56 companies · $902 in 2025
The $902 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $8,415 · 2021: $16K · 2022: $22K · 2023: $4,924 · 2024: $3,983 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,430 · Food and Beverage: $3,358 · Travel and Lodging: $2,001 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,430.00 |
| Food and Beverage | $3,358.21 |
| Travel and Lodging | $2,000.76 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $74,380.76 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $7,173.96 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,530.45 | 2019-2025 | Farxiga, Airsupra |
| Sunovion Pharmaceuticals INC. | $1,260.00 | 2021 | |
| Sumitomo Pharma America, INC. | $907.82 | 2024-2025 | Gemtesa |
| Novo Nordisk INC | $857.87 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $575.31 | 2021-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $513.15 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $394.12 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $383.29 | 2019-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $343.40 | 2022-2024 | |
| Pfizer INC. | $312.26 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $270.06 | 2019-2023 | |
| Lilly USA, LLC | $261.66 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Allergan, INC. | $189.20 | 2019-2020 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zia Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.